PHM Pharma Mar, S.A.
Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Germany, Ireland, France, Switzerland, rest of the European Union, the United States, and internationally. It operates through Oncology and RNA Interference segments. The company offers Yondelis, a synthetic compound derived from the colonial sea squirt ecteinascidia turbinata that treats soft tissue sarcoma and ovarian cancer; Zepzelca, a synthetic compound designed to treat small lung cancer cells; and Aplidin, that is extracted from the ascidian Aplidium albicans to treat patients with multiple myeloma. It also develops LAGOON, which is in Phase III clinical trial for the treatment of small cell lung cancer; SaLuDo, which is in Phase III trial to treat patients with metastatic leiomyosarcoma; as well as PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; and SYL1801 that is in phase II clinical trials for treating and preventing choroidal neovascularization, such as age-related macular degeneration (AMD) and diabetic retinopathy. In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.…
Industry Peers
BiotechnologyKey Statistics
About Pharma Mar (BME: PHM)
›
Pharma Mar (BME: PHM) is listed on the Bolsa de Madrid, where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 505 employees.
The shares were at 59.40 EUR on 19 November 2026, down 24.1% over 52 weeks. Its 52-week range is 58.50 EUR to 105.20 EUR: the price is 43.5% below the high and 1.5% above the low.
At a market capitalisation of 1.02B EUR, it trades at 15.1 times trailing earnings and 15.5 times forward earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.5, a discount of 55% for PHM. It pays a dividend yielding 1.61% (it pays out 25% of its earnings), against a median of 0.94% among the dividend payers in that peer group.
Pharma Mar reports return on equity of 29.8%, an operating margin of 21.3% and revenue up 52.6% year over year.
It holds more cash than debt, a net cash position of 106.23M EUR. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 8 analysts cover the stock, with an average rating of Buy; their mean price target of 98.94 EUR is 66.6% above the current price. The next earnings report is expected on 25 February 2027.